Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open study of Fluarix/Influsplit SSW 2005/2006 influenza vaccine reactogenicity and immunogenicity in adults
2005-001555-38Phase 3Completed
- Sponsor
- GSK
- Start
- Apr 2005
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of Fluarix in influenza (2 arms), sponsored by GSK. Primary endpoints: Humoral immune response by haemagglutination-inhibition geometric mean titers, Seroconversion or significant increase in haemagglutination-inhibition antibodies and 2 more. Started Apr 2005; status: completed.
02
Drugs
Fluarix
03
Conditions
influenza
Beyond the preview
Go deeper on 2005-001555-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001555-38.